Leerink Partners starts BlossomHill Therapeutics at Outperform, $36 target
Leerink Partners initiated coverage on BlossomHill Therapeutics with an Outperform rating and announced a $36.00/share price target.
Ratings actions GMT) BlossomHill Therapeutics Price Target Announced at $36.00/Share by Leerink PartnersRatings actions